Although anti-VEGF drugs still represent the mainstay for the treatment of exudative retinal disorders, including w-AMD and DME, other new therapeutic strategies are being examined with the aim to reduce the treatment burden and improve the efficacy and durability of intravitreal injections [6,10,45,46]. This evidence concerns the gene VEGFA and age-related macular degeneration.